Can Fite Biopharma Aktie [WKN DE: A1W6SX / ISIN: US13471N1028]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Can Fite Biopharma Ltd (spons. ADRs)

28.01.21		Can-Fite’s NASH Indication Highlighted in Webinar by KOL Dr. Harrison: "Namodenoson May Have Big Impact on NASH” (Businesswire)
08.01.21		Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers (Businesswire)
15.12.20		Can-Fite Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery Labs (Businesswire)
14.12.20		Can-Fite Reports on Progress With Its Namodenoson NASH Program (Businesswire)
03.12.20		Can-Fite to Present at Benzinga Global Small Cap Conference on December 8, 2020 (Businesswire)
30.11.20		Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update (Businesswire)
24.11.20		Can-Fite’s Namodenoson Abstract Selected as ‘Best of The Liver Meeting’ in the NASH Category of the American Association of Liver Diseases (AASLD) (Businesswire)
23.11.20		Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET (Businesswire)
16.11.20		Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases (AASLD) Conference (Businesswire)
09.11.20		Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020 (Businesswire)
13.10.20		Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020 (Businesswire)
06.10.20		Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis (Businesswire)
30.09.20		Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases Conference (Businesswire)
22.09.20		Can-Fite to Participate in Two BioPharma Partnering Conferences (Businesswire)
08.09.20		Can-Fite to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 (Businesswire)
31.08.20		FDA Clears Can-Fite to Commence Phase II COVID-19 Study (Businesswire)
27.08.20		Can-Fite Reports Second Quarter 2020 Financial Results & Provides Clinical Update (Businesswire)
25.08.20		Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH (Businesswire)
20.08.20		Can-Fite to Conduct Investor Call to Review Q2 Results and Provide Business Update on Thursday, August 27, 2020 at 4:15 p.m. ET (Businesswire)
27.07.20		Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study (Businesswire)
20.07.20		Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds (Businesswire)
15.07.20		Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly (Businesswire)
06.07.20		Can-Fite Announces $3.4 Million Registered Direct Offering (Businesswire)
30.06.20		Can-Fite Announces Final Data Analysis from Phase II NASH Study: Highly Significant and Sustained Reduction in Liver Fat Volume Throughout Study Period (Businesswire)
10.06.20		Can-Fite Announces $8.0 Million Registered Direct Offering (Businesswire)
08.06.20		Can-Fite Participating in BIO Digital International Convention and One-on-One Partnering Meetings on June 8-12, 2020 (Businesswire)
04.06.20		Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer (Businesswire)
03.06.20		Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on June 4th (Businesswire)
01.06.20		Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update (Businesswire)
28.05.20		Can-Fite to Host First Quarter 2020 Financial Results & Clinical Update Conference Call on June 1, 2020 (Businesswire)
21.05.20		Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office (Businesswire)
18.05.20		Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis (Businesswire)
15.05.20		Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Moderate-to-Severe Symptoms (Businesswire)
14.04.20		Can Fite to Conduct Investor Call to Review Positive Phase II NASH Data on Thursday, April 16, 2020 at 4:05 p.m. ET (Businesswire)
13.04.20		Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately (Businesswire)
07.04.20		Can-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson (Businesswire)
30.03.20		Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020 (Businesswire)
27.03.20		Can-Fite Reports 2019 Financial Results & Provides Clinical Development Update (Businesswire)
23.03.20		Can-Fite: Piclidenoson is Submitted for Compassionate Use Treatment for Coronavirus Patients in Israel (Businesswire)
18.03.20		Can-Fite to Participate in Digital Bio-Europe Spring Partnering Conference; Looks to Partner on Co-Development of Piclidenoson for Coronavirus Treatment (Businesswire)
16.03.20		Can-Fite: Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson (Businesswire)
11.03.20		Can-Fite: New Pre-clinical Studies Demonstrate Inhibition of Fat Cell Expansion by Cannabis Derived CBD (Businesswire)
27.02.20		Pre-clinical Studies Demonstrate CBD’s Robust Anti-Cancer Effect Against Liver Cancer; Can-Fite and Univo Pharmaceuticals Expand Collaboration Agreement (Businesswire)
24.02.20		Can Fite Files Patent for Namodenoson to Overcome Drug Resistance to Checkpoint Inhibitors for Oncology Indications (Businesswire)
18.02.20		Can-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South Korea; Results of its NASH Phase II Study are Expected this Quarter (Businesswire)
13.02.20		Can-Fite Submits Liver Cancer Phase III Protocol and Registration Plan to EMA for Namodenoson (Businesswire)
03.02.20		Can-Fite Completes 50% Patient Enrollment in Phase III Rheumatoid Arthritis Study & Implements Interim Analysis (Businesswire)
16.01.20		Can-Fite and Univo Pharmaceuticals Collaboration Result in Discovery and Applied Patent for Cannabinoid Formulations with Broad Therapeutic Effects (Businesswire)
09.01.20		Can-Fite Announces Exercise of Warrants for Cash Proceeds of $2.4 Million (Businesswire)
07.01.20		Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer (Businesswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Bitcoin als Chance: MicroStrategy-Chef fordert Microsoft zu mutigem Schritt auf

CompuGroup-Aktie mit zweistelligem Plus: CVC bestätigt Akquisition

Bayer-Aktie erholt sich weiter: Glyphosat-Fehlprozess in USA

Neue Kooperationsvereinbarung: Palantir-Aktie erreicht neues Rekordhoch - und sackt dann ab

Generative KI: Warum der NVIDIA-CEO auf Accenture setzt

voestalpine-Aktie gewinnt: Wiener Privatbank senkt Kursziel

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	11.12.2024 20:56
Kaufwert:	EUR
	Hinzufügen Speichern